Literature DB >> 91457

Decreased sialic acid and altered binding to lectins of purified alpha 2-macroglobulin from patients with cystic fibrosis.

Y Ben-Yoseph, C L Defranco, H L Nadler.   

Abstract

Purified preparations of plasma alpha 2-macroglobulin from patients with cystic fibrosis are shown to have normal amounts of total hexose but as much as 40% decrease in their sialic acid content. The binding of these preparations to concanavalin A and wheat-germ agglutinin was markedly reduced as compared to normal values in controls. Intermediate values were found in obligate heterozygotes. These results suggest a possible alteration in the carbohydrate moiety of alpha 2-macroglobulin in cystic fibrosis, presumably due to a defective posttranslational process.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 91457     DOI: 10.1016/0009-8981(79)90136-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Glycoproteins in cystic fibrosis: a lectin binding study.

Authors:  S Karlsson; B Griffiths; D M Swallow; D A Hopkinson; P G Wallis
Journal:  J Med Genet       Date:  1984-12       Impact factor: 6.318

2.  Biosynthesis of mucin type O-glycans: lack of correlation between glycosyltransferase and sulfotransferase activities and CFTR expression.

Authors:  I Brockhausen; F Vavasseur; X Yang
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

3.  The interrelations between high- and low-molecular weight forms of normal and mutant (Krabbe-disease) galactocerebrosidase.

Authors:  Y Ben-Yoseph; M Hungerford; H L Nadler
Journal:  Biochem J       Date:  1980-07-01       Impact factor: 3.857

4.  Normal two-dimensional gel electrophoresis of alpha-2-macroglobulin in cystic fibrosis.

Authors:  D E Comings; L C LeFever; Y Ben-Yoseph; H L Nadler
Journal:  Am J Hum Genet       Date:  1980-03       Impact factor: 11.025

5.  Modifications of plasma fibronectin in cystic fibrosis patients.

Authors:  L Stanislawski; M Sorin
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.